MYCOSTER

1 % · cream · 1 tube 30 g

CICLOPIROXOLAMINE

Reference dated : 2017-12-18. Confirm price and availability with a pharmacist.

Public price

45,20 MAD

Composition and presentation

MYCOSTER — CICLOPIROXOLAMINE. Listed presentation: 1 % · CREME · 1 TUBE 30 G.

Full clinical reference

Additional sections are available in French. Read the original document; the information concerns the French reference product.

Uses

Dermatoses superinfected or not by bacteria:

· dermatophytoses caused by Trichophyton,

· Epidermophyton, Microsporum outside of tinea capitis,

· cutaneous candidiasis,

· pityriasis versicolor,

· Onychomycoses caused by dermatophytes.

Mild to moderate seborrheic dermatitis of the face.

Interactions

No interaction studies have been conducted.

Driving

CICLOPIROX OLAMINE BIOGARAN has no effect on the ability to drive vehicles and use machines.

Adverse effects

The following table presents the adverse effects by MedDRA system organ class.

Frequencies are defined as: very frequent (≥ 1/10), frequent (≥ 1/100, < 1/10), uncommon (≥ 1/1000, < 1/100), rare (≥ 1/10 000, < 1/1000), very rare (< 1/10 000), undetermined (cannot be estimated from the available data).

System organ class Frequency	MedDRA preferred term
Immune system disorders Uncommon	Hypersensitivity*
Skin and subcutaneous tissue disorders Frequent	Burning sensation
Undetermined frequency	Contact dermatitis**
General disorders and administration site conditions Frequent	Transient exacerbation of local signs at the application site, Erythema at the application site ** * Pruritus at the application site***
Uncommon	Vesicles at the application site*

* requires interruption of treatment

** cases of contact dermatitis have been reported since marketing

*** does not require discontinuation of treatment

The possibility of occurrence of systemic effects must be taken into account in case of prolonged treatment over a large area, on damaged skin, a mucosa or under an occlusive dressing.

Reporting of suspected adverse effects

Reporting of suspected adverse effects after authorisation of the medicinal product is important. It allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare professionals report any suspected adverse effect via the national reporting system: French National Agency for Medicines and Health Products Safety (ANSM) and the network of Regional Pharmacovigilance Centres - Website: https://signalement.social-sante.gouv.fr/

Read the French reference

Hospital price

28,20 MAD

Type

Originator

Therapeutic class

ANTIFONGIQUE

References and update dates

CNOPS Referentiel des medicaments · 2017-12-18

Product and price reference

This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.

Price history

Reference price recorded since 2017-12-18: 45,20 MAD

Same ingredient, strength and form

This grouping does not establish interchangeability.

BRUMIXOL

1 % · cream · 1 tube 30 g

37,80 MAD

Other strengths and forms

Routes and instructions may differ.